top of page
Connect_Logo_CMYK.jpg
Connect_Logo_CMYK.png
iStock-184117476.jpg

Publications & Presentations

Rademikibart - Dermatology
Optimized Second-Generation IL-4Rα Inhibition: Structural and Molecular Dynamics Properties of Rademikibart Fab-IL-4Rα Complex

Presented at the 44th Annual Fall Clinical (FC) Dermatology Conference, October 24-27, 2024

Abstract
Poster
Rademikibart (IL-4RαBlocker) Integrated Exposure-Response Analysis Supports Differentiated Once Monthly Dosing Regimen

Presented at the European Academy of Dermatology and Venereology Congress (EADV), September 25-28, 2024

Abstract
Poster
Maintenance of Investigator and Patient Reported Outcomes over 52 Weeks were Observed with Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis (SEASIDE CHINA)

Presented at the European Academy of Dermatology and Venereology Congress (EADV), September 25-28, 2024

Abstract
Poster
Continued Improvement of Investigator and Patient Reported Outcomes into the 52-Week Maintenance Period were Observed with Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis (SEASIDE CHINA)

Presented at the European Academy of Dermatology and Venereology Congress (EADV), September 25-28, 2024

Abstract
Poster
Abstract
Presentation
Positive 52-Week Maintenance Data Observed with Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis - SEASIDE CHINA

Presented at the Revolutionizing Atopic Dermatitis (RAD 2024) Conference, June 8-10, 2024

Rademikibart (CBP-201) a next-generation IL-4Rα antibody, achieved all primary and secondary endpoints in a randomized pivotal trial for moderate-to-severe atopic dermatitis (AD) in China 

Presented at the World Congress of Dermatology (WCD), July 3-8, 2023

Abstract
Poster
Eczema Area and Severity Index (EASI) scores improved, and encouraging safety and tolerability were observed, across 16 weeks of treatment with rademikibart (CBP-201) for moderate-to-severe  atopic dermatitis (AD) A pivotal trial in China (CBP-201-CN002)

Presented at the World Congress of Dermatology (WCD), July 3-8, 2023

Abstract
Poster
Improvements in investigator-rated outcomes across 16 weeks of treatment with rademikibart (CBP-201) for moderate-to-severe atopic dermatitis (AD): Results from a pivotal trial in China (CBP-201-CN002)

Presented at the World Congress of Dermatology (WCD), July 3-8, 2023

Abstract
Poster
Improvements in patient-reported outcomes (PROs) across 16 weeks of treatment with rademikibart (CBP-201) for moderate-to-severe atopic dermatitis (AD): Results from a pivotal trial in China 

Presented at the World Congress of Dermatology (WCD), July 3-8, 2023

Abstract
Poster
Potentially Greater Efficacy with CBP-201 for Adults with Severe versus Moderate Atopic Dermatitis at Baseline: Subgroup Analyses from the WW001 Phase 2 Randomized Trial

Presented at the Revolutionizing Atopic Dermatitis (RAD) Conference, April 30, 2023

Abstract
Poster
CBP-201, a next-generation IL-4Rα antibody, achieved all primary and secondary efficacy endpoints in the treatment of adults with moderate-to-severe atopic dermatitis (AD): A randomized, double-blind, pivotal trial in China (CBP-201-CN002)

Presented at the American Academy of Dermatology (AAD) Annual Meeting, March 17-21, 2023

Abstract
Presentation
Rapid and Sustained Improvements with CBP-201 Across All Body Regions: Treatment of Atopic Dermatitis in a Phase 2b, Randomized, Double-blind, Placebo-controlled Trial (CBP-201-WW001)

Presented at the American Academy of Dermatology (AAD) Annual Meeting, March 17-21, 2023

Abstract
Presentatin
CBP-201: A Next Generation IL-4Rα Blocker

Oral presentation at the 6th Annual Dermatology Drug Development Summit (DDDS), November 1–3, 2022

No Abstract
Presentation
Investigator-Rated Efficacy Outcomes Across 16 Weeks of Treatment with CBP-201: Results from a Phase 2b Trial in Patients with Atopic Dermatitis (CBP-201-WW001)

Presented at the 31st European Academy of Dermatology and Venereology Congress (EADV), September 7-10, 2022

Abstract
Poster
Patient-Reported Efficacy Outcomes Across 16 Weeks of Treatment with CBP- 201: Results from a Phase 2b Trial in Patients with Atopic Dermatitis (CBP-201- WW001)

Presented at the 31st European Academy of Dermatology and Venereology Congress (EADV), September 7-10, 2022

Abstract
Poster
CBP-201, a novel and differentiated IL-4Rα targeting antibody being evaluated in Th2 inflammatory diseases

Presented at the Society for Investigative Dermatology (SID) Annual Meeting, May 18-21, 2022

Abstract
Poster
Disease Control and Quality of Life: Efficacy Outcomes from the Phase 2b Trial of CBP-201 in Patients with Atopic Dermatitis (CBP-201-WW001)

Presented at the Revolutionizing Atopic Dermatitis (RAD) Conference, April 9 - 11, 2022

Abstract
Poster
Efficacy and Safety of CBP-201 in Adults with Moderate-to-Severe Atopic Dermatitis (AD): A Phase 2b, Randomized, Double-blind, Placebo-controlled Trial (CBP-201-WW001)

Presented at the Maui Derm Conference, January 24, 2022

Abstract
Poster
The Effect of Baseline Disease Characteristics on Efficacy Outcomes: Results from a Phase 2b, Randomized, Double-blind, Placebo-controlled Trial of CBP-201 in Adults with Moderate-to-Severe Atopic Dermatitis (AD)

Presented at the Maui Derm Conference, January 24, 2022

Abstract
Poster
A randomized, double-blind, placebo-controlled, multiple ascending dose study of the safety, pharmacokinetics and preliminary efficacy of CBP-201 in adult patients with moderate to severe atopic dermatitis (CPB-201AU002)

Presented at the 29th European Academy of Dermatology and Venereology Congress (EADV), October 29, 2020

No Abstract
Poster
bottom of page